1. Home
  2. HUMAW

as of 04-27-2026 1:29pm EST

$0.08
$0.01
-7.83%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Founded: 2004 Country:
United States
United States
Employees: 184 City: DURHAM
Market Cap: N/A IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 14.7K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.36 EPS Growth: N/A
52 Week Low/High: $0.06 - $0.60 Next Earning Date: 03-21-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: -0.06 Index: N/A
Free Cash Flow: -92258000.0 FCF Growth: N/A

Share on Social Networks: